1. "2016"
  2. "Journal for ImmunoTherapy of Cancer"
Formats
  1. Meeting Abstract (25)
  2. Journal Article (6)
Groups
  1. Department of Medicine (26)
  2. Solid Tumor Oncology Division (22)
  3. GSK Faculty (11)
  4. Melanoma and Immunotherapeutics Service (10)
  5. Sloan Kettering Institute Postdocs (9)
  6. Genitourinary Oncology Service (8)

More Groups

People
  1. Jedd Wolchok (8)
  2. Taha Merghoub (7)
  3. Margaret Callahan (3)
  4. Matthew Hellmann (3)
  5. Neil Segal (3)
  6. Roberta Zappasodi (3)

More People

Years
  1. 2016 (31)
Publications
  1. Journal for ImmunoTherapy of Cancer (31)
Publishers
  1. Biomed Central Ltd (31)

Results (31)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genome-scale neoantigen screening using ATLAS™ prioritizes candidates for immunotherapy in a non-small cell lung cancer patient
    Meeting Abstract

    Ghamsari, L.; Flano, E.; Jacques, J.; Liu, B.; Havel, J.; Makarov, V.; Merghoub, T.; Wolchok, J. D.; Hellmann, M. D.; Chan, T. A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Intratumoral delivery of modified vaccinia virus Ankara expressing human flt3L as cancer immunotherapy
    Meeting Abstract

    Dai, P.; Wang, W.; Yang, N.; Shuman, S.; Merghoub, T.; Wolchok, J. D.; Deng, L.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Assessing the potential for enhanced antibody-dependent cellmediated cytotoxicity (ADCC) by combining the CD137 antibody urelumab with rituximab or cetuximab in patients with refractory lymphoma or select advanced solid tumors
    Meeting Abstract

    Segal, N. H.; Sharma, M.; Le, D. T.; Ott, P. A.; Ferris, R. L.; Zelenetz, A. D.; Neelapu, S. S.; Levy, R.; Lossos, I. S.; Jacobson, C.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Opposing effects of CTLA-4 and PD-1 blockade on follicular helperlike T cells with immunosuppressive functions
    Meeting Abstract

    Zappasodi, R.; Budhu, S.; Hellmann, M. D.; Postow, M.; Senbabaoglu, Y.; Gasmi, B.; Zhong, H.; Li, Y.; Liu, C.; Hirschhorhn-Cymerman, D.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Initial experience administering BMS-986016, a monoclonal antibody that targets lymphocyte activation gene (LAG)-3, alone and in combination with nivolumab to patients with hematologic and solid malignancies
    Meeting Abstract

    Lipson, E.; Gopal, A.; Neelapu, S. S.; Armand, P.; Spurgeon, S.; Leonard, J. P.; Hodi, F. S.; Sanborn, R. E.; Melero, I.; Gajewski, T. F.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Immune activation by PEGylated human IL-10 (AM0010) and anti-tumor activity in renal cancer alone and in combination with anti-PD-1
    Meeting Abstract

    Naing, A.; Papadopoulos, K. P.; Autio, K. A.; Wong, D. J.; Patel, M.; Falchook, G.; Pant, S.; Ott, P. A.; Whiteside, M.; Patnaik, A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Local intratumoral treatment with low-dose CD40 and TLR4 agonists overcomes resistance to PD-1 blockade to control tumors systemically
    Meeting Abstract

    Khalil, D. N.; Campesato, L. F.; Li, Y.; Merghoub, T.; Wolchok, J. D.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Dose escalation/confirmation results of ENCORE 601, a phase Ib/II, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Johnson, M. L.; Adjei, A. A.; Opyrchal, M.; Ramalingam, S.; Janne, P. A.; Dominguez, G.; Gabrilovich, D.; de Leon, L.; Hasapidis, J.; Diede, S. J.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Phosphatidylserine targeting antibody in combination with checkpoint blockade and tumor radiation therapy promotes anticancer activity in mouse melanoma
    Meeting Abstract

    Budhu, S.; De Henau, O.; Zappasodi, R.; Schlunegger, K.; Freimark, B.; Hutchins, J.; Barker, C. A.; Wolchok, J. D.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • CX-839-004: A phase I/II study of the safety, pharmacokinetics, and pharmacodynamics of the glutaminase inhibitor CB-839 combined with nivolumab in patients with renal cell carcinoma, melanoma, and non-small cell lung cancer
    Meeting Abstract

    Lam, E.; Tannir, N. M.; Meric-Bernstam, F.; Vaishampayan, U.; Orford, K. W.; Molineaux, C.; Gross, M.; MacKinnon, A.; Voss, M.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save